Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications
Early-Onset Hemophagocytic Lymphohistiocytosis and Inflammatory Neurotoxicity Prior to Post-transplant Cyclophosphamide: A Report of Two Cases.
Journal: Cureus
Published: July 14, 2026
Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma.
Journal: JCO clinical cancer informatics
Published: March 20, 2026
System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost.
Journal: Transplantation and cellular therapy
Published: March 12, 2026
Brute force: the effects of ibrutinib on brexu-cel.
Journal: Blood advances
Published: February 24, 2026
Brute force: the effects of ibrutinib on brexu-cel.
Journal: Blood advances
Published: February 13, 2026
Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel.
Journal: Journal of the neurological sciences
Published: December 11, 2025
Higher HLA-DRB1 Evolutionary Divergence Is Associated with Reduced Relapse and Improved Survival after Matched Unrelated Hematopoietic Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: October 28, 2025
Expanded antigen-specific donor regulatory T cells for GVHD prevention.
Journal: Blood
Published: July 02, 2025
Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202.
Journal: Blood vessels, thrombosis & hemostasis
Published: June 12, 2025
ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device.
Journal: Bone marrow transplantation
Published: May 19, 2025
Last Updated: 09/26/2026